GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

Publish in print Wednesday, Friday and Saturday ... our online GARAGE SALE section of local.postregister.com, with your ad plus a map to your location. A garage sales kit including signs, pricing ...

There are two other vaccines already available in Canada to protect seniors against severe illness caused by RSV: Arexvy, manufactured by GSK, and Abrysvo, made by Pfizer. Earlier this year ...

In its Q3 results, GSK (NYSE:GSK), the first to receive U.S. approval for an RSV vaccine in May 2023, said its Arexvy vaccine added £188M in sales, indicating ~ a 73% YoY drop. The British ...

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower respiratory tract disease due to underlying chronic conditions.

TORONTO - Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — but it won’t be available until next year, the company ...